Gilead reports positive long-term data for Yescarta for NHL (NASDAQ:GILD)


Gilead reports positive long-term data for Yescarta for NHL (NASDAQ:GILD)

Sundry Photography

Gilead’s (NASDAQ:GILD) Kite unit reported positive results from a five-year follow-up of a Phase 2 study for its cell therapy Yescarta in certain patients with non-Hodgkin lymphoma, or NHL.

The analysis showed that after a median follow-up of more than



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

LATEST POSTS

Dark web, cryptocurrency, drones continue to be challenge: Amit Shah | India News

NEW DELHI: Union home minister Amit Shah said on Saturday that dark web, cryptocurrency, online marketplace and drones continue to be a...

Insurers gain Wall Street’s vote of confidence, with caveats (KIE:NYSEARCA)

Jan. 11, 2025 4:15 PM ETSPDR® S&P Insurance ETF (KIE)PGR, ALL, UNM, MMC, GL, PFG, CB, MCY, EHTH, WTW, KMPR, TRV, AON, KINS, ROOTBy:...

Follow us

653FansLike
201FollowersFollow
467SubscribersSubscribe

Most Popular